anonymous manner. Genomic DNA was extracted from these and telomere length measured by telomere PCR. Each telomere length was expressed as a ratio (telomere length: single copy gene). Telomerase activity was measured using Roche Telo TAAGGG ELISA kit. All samples were analysed in duplicate and investigators were semi-blinded to arrhythmia history. Continuous data were compared using unpaired t test and categorical data by χ^2 test. Logistic regression analysis was performed to determine if telomere length/telomerase activity independently predict the likelihood of a shock (fatal VA). A probability value of $p < 0.05$ was defined as significant.

Results There were no significant differences between the Shock (patients received appropriate shocks from ICD; $n=25$) and Non-shock (patients received no shock; $n=48$) groups in terms of baseline demographics as shown in Abstract 056 table 1. There was no significant difference in the age, sex and WCC adjusted telomere length between the Shock and Non-shock groups ($p=0.439$). Expected age and WCC turnover related telomere attrition ($p=0.031$ and 0.031) was observed. In contrast, telomerase activity was significantly higher in the Shock group than in the Non-shock group (0.5682 vs 0.2105) and co-related to the incidence of shock ($p=0.01$). This did not appear to be related to an acute response associated with VA.

Abstract 056 Table 1

	Group1 (shock)	Group 2 (non-shock)	p Value
Number of patients	25	48	
Age, mean (range)	70.8 (56–87)	70.8 (46–87)	0.97
Female gender (%)	4	16.67	0.15
Diabetes (%)	5 (20)	14 (29.2)	0.57
Hypertension (%)	5 (20)	14 (29.2)	0.57
Time since implant (months), mean	50.68	34.13	0.06
LVEF	27.64	27.29	0.84

Conclusion This is the first study to characterise the telomere dynamics of patients at high risk of sudden cardiac death and correlate this with the incidence of VA. Leucocyte telomerase activity independently predicted the likelihood of shock in ischaemic cardiomyopathy patients with primary prevention ICDs. Thus leucocyte telomerase activity may be a potential biomarker for prediction of fatal arrhythmia and guide ICD prescription. To validate these results, a prospective study is now ongoing.

057 A RANDOMISED CONTROLLED TRIAL OF CATHETER ABLATION VS MEDICAL TREATMENT OF ATRIAL FIBRILLATION IN HEART FAILURE (THE CAMTAF TRIAL)

doi:10.1136/heartjnl-2012-301877b.57

¹R J Hunter, ^{*} ¹T J Berriman, ¹I Diab, ¹R Kamdar, ¹L Richmond, ¹V Baker, ¹F Goromonzi, ¹E Duncan, ¹V Sawhney, ²B Unsworth, ²J Mayet, ¹M Dhinoja, ¹M J Earley, ¹S Sporton, ¹R J Schilling. ¹St Bartholomew's Hospital, London, UK; ²International Centre for Circulatory Health, St Mary's Hospital, Imperial College London, London, UK

Introduction Although atrial fibrillation (AF) has deleterious effects in patients with heart failure (HF), rhythm control using medication has limited efficacy. Catheter ablation (CA) of AF is effective in restoring sinus rhythm, raising the question: if it can be shown to be safe and effective in HF patients, might it improve left ventricular (LV) function and HF symptoms? We sought to compare the impact of a CA strategy to a medical rate control strategy (MED) in patients with persistent AF and HF.

Methods Patients with persistent AF, symptomatic HF, and a LV ejection fraction (EF) $< 50\%$, were randomised to CA or MED. HF medication and anticoagulation were optimised prior to baseline observations. For those with recurrent AF in the CA group, a repeat

procedure was performed at the end of the 3-month blanking period and follow-up re-started. The primary end-point was the difference in LV EF between groups on echocardiography at 6 months. Echocardiographic data were anonymised and core reported by a blinded collaborating centre. Secondary end-points included difference in NYHA class, Minnesota living with heart failure questionnaire score, and peak oxygen consumption at 6 months.

Results 55 patients were randomised, but five were excluded (LV function normalised during optimisation of medications prior to baseline tests in 2, and 3 withdrew unhappy with their treatment allocation). Patients were 58 ± 11 years and 96% were male. Baseline LV EF was $31 \pm 10\%$ in the CA group and $33 \pm 9\%$ in the MED group. NYHA class was 2.5 ± 0.5 in both groups. Patients underwent 1.6 ± 0.7 procedures. There were two complications: (1) stroke and 1 tamponade. In the CA group 1 patient withdrew after a procedural stroke, and in the MED group 1 patient died. In total 21 of 24 in the MED group and 24 of 26 in the CA group had reached 6-months follow-up and were included in this analysis of the primary end-point. Freedom from AF was achieved in 21/24 (88%) off antiarrhythmic drugs in the CA group, whereas all those in the MED group remained in AF. LV EF in the CA group at 6 months was $39 \pm 10\%$ compared to $32 \pm 13\%$ in the MED group ($p < 0.05$). NYHA class was also significantly lower in the CA group at 6 months (1.7 ± 0.8 compared to 2.3 ± 0.6 in the medical group; $p < 0.05$). CA was associated with better peak oxygen consumption (22.4 ± 6.3 ml/kg/min vs 18.6 ± 6.0 ml/kg/min, $p=0.053$) and Minnesota living with heart failure questionnaire score (24 ± 23 vs 48 ± 25 , $p=0.002$) compared to the MED group.

Conclusions CA is effective in restoring sinus rhythm in the majority of patients with persistent AF. A CA strategy for patients with AF and HF is associated with improved LV function and heart failure symptoms compared to medical treatment alone.

058 THE RELATIONSHIP OF LEFT ATRIAL REMODELLING TO ATRIAL FIBRILLATION BURDEN IN PACEMAKER POPULATION

doi:10.1136/heartjnl-2012-301877b.58

C W Khoo, ^{*} S Krishnamoorthy, G Dwivedi, A Blann, H S Lim, G Y H Lip. University Department of Medicine Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

Background Cumulative ventricular pacing (VP) is associated with development of atrial fibrillation and cardiac remodelling. Contemporary pacemaker devices are able to quantify atrial high-rate episodes (AHREs) and atrial fibrillation burden (AFB). No previous study has investigated the relationship of reverse LA remodelling and AHRE. We tested the hypothesis that reverse LA remodelling parameters are associated with greater AF burden and larger percentage of cumulative ventricular pacing in pacemaker population.

Methods 101 patients [mean age 72 ± 11 years, 69 (68%) men], mean follow-up of 359.09 ± 83.85 days] with dual-chamber pacemaker underwent two-dimensional (2D) and tissue Doppler imaging (TDI) echocardiography. LA volume (LAV) was evaluated by area-length method and function by septal A'. LV systolic and diastolic parameters were evaluated by mitral inflow velocity (E, A), LV ejection fraction (biplane Simpson's) and septal TDI velocity. The presence of AHREs (defined by atrial-rate ≥ 220 bpm and ≥ 5 min) and AFB were derived from pacemaker diagnostics.

Results The incidence of AHRE in our study was 35% ($n=35$) with median percentage AF burden of 2.6 (IQR 0.1–26.4). Patients with AHREs had significantly larger LA volume ($p=0.014$) and reduced LA function at follow-up ($p=0.034$), as were LV diastolic parameters, LV and RV longitudinal systolic function (all $p < 0.05$) [Abstract 058